Medpace (MEDP) Expected to Announce Earnings on Monday

Medpace (NASDAQ:MEDP) will likely be issuing its quarterly earnings data after the market closes on Monday, February 10th. Analysts expect the company to announce earnings of $2.96 per share and revenue of $534.99 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Medpace Price Performance

Medpace stock opened at $354.10 on Friday. The business has a 50 day simple moving average of $343.61 and a 200 day simple moving average of $350.38. Medpace has a one year low of $302.01 and a one year high of $459.77. The company has a market capitalization of $11.01 billion, a PE ratio of 31.01, a price-to-earnings-growth ratio of 1.79 and a beta of 1.36.

Wall Street Analyst Weigh In

MEDP has been the topic of several recent analyst reports. TD Cowen reduced their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Redburn Atlantic initiated coverage on shares of Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target on the stock. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird boosted their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.